Abstract
Zanubrutinib, marketed as Brukinsa, is a Bruton's tyrosine kinase (BTK) inhibitor developed by BeiGene for the treatment of various B-cell malignancies. Since its approval in 2019, it has demonstrated significant clinical efficacy and has been introduced into multiple global markets. This paper provides an in-depth analysis of zanubrutinib, covering its chemical properties, development history, approval timeline, market presence, competitive landscape, and the emergence of generic formulations. Additionally, it offers speculative sales figures from 2020 to 2024 based on available data and market trends.
Keywords
Zanubrutinib, Brukinsa, Bruton's tyrosine kinase inhibitor, chemical properties, market analysis, global sales, generics.
Introduction
Zanubrutinib is an oral BTK inhibitor designed to provide sustained inhibition of the BTK protein, playing a crucial role in the proliferation and survival of malignant B cells. Its development offers a therapeutic option for patients with various hematologic cancers, including mantle cell lymphoma (MCL), Waldenström's macroglobulinemia (WM), marginal zone lymphoma (MZL), chronic lymphocytic leukemia (CLL), and follicular lymphoma (FL).
Chemical Properties
Zanubrutinib has the chemical formula C27H29N5O3 and a molar mass of approximately 471.56 g·mol−1. Its IUPAC name is 1-[(3R)-3-[4-Amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl]piperidin-1-yl]prop-2-en-1-one. The compound's structure enables selective and irreversible inhibition of BTK, contributing to its efficacy in treating B-cell malignancies.
Development and Approval Timeline
November 2019: The U.S. FDA granted accelerated approval for zanubrutinib to treat patients with MCL who have received at least one prior therapy.
August 2021: FDA approved zanubrutinib for treating WM.
September 2021: FDA approved zanubrutinib for treating MZL.
January 2023: FDA approved zanubrutinib for treating CLL/SLL.
March 2024: FDA granted accelerated approval to zanubrutinib, in combination with obinutuzumab, for relapsed or refractory FL after two or more lines of systemic therapy.
Zanubrutinib is approved in more than 70 markets globally, with over 180,000 patients treated as of early 2024.
Time on the Market
Since its initial approval in 2019, zanubrutinib has been available for over five years. Its sustained presence in the market underscores its significance in treating B-cell malignancies, with ongoing research potentially expanding its therapeutic applications.
Global Sales and Market Competition
In 2024, zanubrutinib achieved notable sales milestones:
U.S. Sales: Totaled $2.0 billion for the year, with $616 million in Q4, marking a 97% year-over-year growth.
European Sales: Reached $359 million for the year, with $113 million in Q4, representing a 194% year-over-year growth.
The BTK inhibitor market is competitive, with alternatives like ibrutinib (Imbruvica) and acalbrutinib (Calquence) present. Zanubrutinib differentiates itself with its unique pharmacokinetic profile, offering once or twice daily dosing options.
Generics and Related Developments
As of March 2024, BeiGene entered into a settlement agreement with MSN Pharmaceuticals, allowing MSN to sell a generic version of BRUKINSA in the U.S. no earlier than June 15, 2037, subject to certain conditions.
Speculated Sales Figures (2020–2024)
Based on available data and market trends, estimated global sales of zanubrutinib are as follows
2020: Approximately $160 million.
2021: Approximately $450 million (first three quarters).
2022: Approximately $600 million.
2023: Approximately $1.0 billion.
2024: Projected around $2.0 billion.
The significant growth in 2023 and 2024 is attributed to expanded approvals, increased market adoption, and effective marketing strategies.
Conclusion
Zanubrutinib has substantially impacted the treatment landscape for B-cell malignancies since its introduction, offering patients effective therapeutic options. Its market trajectory reflects both its clinical value and the evolving dynamics of the pharmaceutical industry, including competition, pricing strategies, and the introduction of generic alternatives. Ongoing research and market adaptations will continue to shape its role in oncology therapeutics.
Active Pharmaceutical Ingredient
1691249-45-2
Zanubrutinib, (chemical grade, purity ≥99.0%) are currently supplied by our company. [Own compliance factory, fully support factory audit] For details, you can call the bottom line to get the latest price of the product!
Disclaimer:Products are only available to countries where there is no valid patent protection. Products still covered by patents rights are available exclusively for experimental or registration purpose pursuant to national applicable law, and shall be sold in strict accordance with the laws of the People's Republic of China and the laws of the Buyer's country. All products are not for human use. Buyer is obligated for evaluation of the patent situation in its domestic market and shall be held liable for uses which do not fall within the scope of the experimental or registration use exception and are not permitted by national applicable law.
References or other information:
FDA、Wikipedia、Chatgpt、DeepSeek、chemicalbook
If there is any infringement, please apologize and delete. If there are any errors, welcome to criticize and correct.
Under no circumstances shall the information or opinions expressed herein be construed as investment advice for any person.
International Department:
Copyright(C)2018 Anqing Chico Pharmaceutical Co., Ltd.
Supported byChinaChemNet
